{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:26:27Z","timestamp":1777569987569,"version":"3.51.4"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We describe novel rifamycin derivatives (new chemical entities [NCEs]) that retain significant activity against a comprehensive collection of\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            strains that are resistant to rifamycins. This collection of resistant strains contains 21 of the 26 known single-amino-acid alterations in RpoB, the target of rifamycins. Some NCEs also demonstrated a lower frequency of resistance development than rifampin and rifalazil in\n            <jats:italic>S. aureus<\/jats:italic>\n            as measured in a resistance emergence test. When assayed for activity against the strongest rifamycin-resistant mutants, several NCEs had MICs of 2 \u03bcg\/ml, in contrast to MICs of rifampin and rifalazil, which were 512 \u03bcg\/ml for the same strains. The properties of these NCEs therefore demonstrate a significant improvement over those of earlier rifamycins, which have been limited primarily to combination therapy due to resistance development, and suggest a potential use of these NCEs for monotherapy in several clinical indications.\n          <\/jats:p>","DOI":"10.1128\/aac.50.3.827-834.2006","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T07:32:35Z","timestamp":1140593555000},"page":"827-834","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":36,"title":["In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant\n            <i>Staphylococcus aureus<\/i>"],"prefix":"10.1128","volume":"50","author":[{"given":"Christopher K.","family":"Murphy","sequence":"first","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Mullin","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia S.","family":"Osburne","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"van Duzer","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Siedlecki","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Yu","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Kerstein","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, 136 Harrison Ave., Boston, Massachusetts 02111"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cynamon","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center and State University of New York, Upstate Medical University, 800 Irving Ave., Syracuse, New York 13210"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Rothstein","sequence":"additional","affiliation":[{"name":"ActivBiotics, Inc., Lexington, Massachusetts 02421"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2590"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.1866"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00286-0"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1139\/o73-170"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2005.11.107"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.1972-1976.2001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2316-2318.2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1118"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(76)90040-X"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(67)90147-5"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.1.107-110.2001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1713-1715.2000"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00036-0"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2283-2287.2004"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238006"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/119.2.132"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.903-907.2005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.17.4.658"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2655"},{"key":"e_1_3_2_21_2","first-page":"1477","volume":"52","year":"2002","unstructured":"Morse, R., K. O'Hanlon, and M. D. Collins. 2002. Phylogenetic, amino acid content and indel analyses of the beta subunit of DNA-dependent RNA polymerase of gram-positive and gram-negative bacteria. Int. J. Syst. Evol. Microbiol.52:1477-1484.","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.9.2913-2919.1999"},{"key":"e_1_3_2_23_2","unstructured":"Approved standard M7-A6 2003 vol. 23"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3163-3166.2000"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.5.647"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2361"},{"key":"e_1_3_2_27_2","first-page":"166","volume":"6","year":"2002","unstructured":"Park, Y. K., B. J. Kim, S. Ryu, Y. H. Kook, Y. K. Choe, G. H. Bai, and S. J. Kim. 2002. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis.6:166-170.","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.2.255"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2425-2431.2004"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3229-3231.2000"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01139.x"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.443-450.2002"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.2.181"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1120-1126.2005"},{"key":"e_1_3_2_35_2","unstructured":"van Duzer J. H. A. F. Michaelis W. B. Geiss D. G. Stafford and J. Raker. Feb. 2005. Rifamycin analogs and uses thereof. U.S. patent 2005\/0043298."},{"key":"e_1_3_2_36_2","unstructured":"van Duzer J. H. A. F. Michaelis W. B. Geiss D. G. Stafford X. Y. Yu J. M. Siedlecki and Y. Yang. June 2005. Rifamycin analogs and uses thereof. U.S. patent 2005\/0137189."},{"key":"e_1_3_2_37_2","unstructured":"van Duzer J. H. A. F. Michaelis W. B. Geiss D. G. Stafford J. Raker X. Y. Yu J. M. Siedlecki and Y. Yang. Sept. 2005. Rifamycin analogs and uses thereof. U.S. patent 2005\/0197333."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2787(68)90285-2"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S407"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3381-3385.2002"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.2.153"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2813"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1853"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2380"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.5.621"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki053"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.5.2209-2212.2003"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1244-1248.2001"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.19.1537"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.3.827-834.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.50.3.827-834.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:58:53Z","timestamp":1645469933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.50.3.827-834.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1128\/AAC.50.3.827-834.2006"],"URL":"https:\/\/doi.org\/10.1128\/aac.50.3.827-834.2006","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2005-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}